QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
48.29 USD
-0.16 (-0.33%)
48.29 USD
0 (0%)
Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 57 industry peers in the Life Sciences Tools & Services industry. QGEN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. QGEN has a correct valuation and a medium growth rate. These ratings would make QGEN suitable for quality investing!
1. Profitability
1.1 Basic Checks
QGEN had positive earnings in the past year.
QGEN had a positive operating cash flow in the past year.
Each year in the past 5 years QGEN has been profitable.
QGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
QGEN has a better Return On Assets (6.19%) than 82.46% of its industry peers.
The Return On Equity of QGEN (11.11%) is better than 82.46% of its industry peers.
QGEN has a better Return On Invested Capital (7.44%) than 78.95% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 14.00%.
The last Return On Invested Capital (7.44%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN's Profit Margin of 19.58% is amongst the best of the industry. QGEN outperforms 94.74% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
Looking at the Operating Margin, with a value of 27.02%, QGEN belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
QGEN's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 64.10%, QGEN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), QGEN is destroying value.
QGEN has less shares outstanding than it did 1 year ago.
QGEN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, QGEN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.62 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN's Altman-Z score of 3.62 is fine compared to the rest of the industry. QGEN outperforms 68.42% of its industry peers.
The Debt to FCF ratio of QGEN is 4.50, which is a neutral value as it means it would take QGEN, 4.50 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 4.50, QGEN is doing good in the industry, outperforming 73.68% of the companies in the same industry.
A Debt/Equity ratio of 0.45 indicates that QGEN is not too dependend on debt financing.
The Debt to Equity ratio of QGEN (0.45) is worse than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.62 |
ROIC/WACC0.88
WACC8.42%
2.3 Liquidity
A Current Ratio of 2.60 indicates that QGEN has no problem at all paying its short term obligations.
The Current ratio of QGEN (2.60) is comparable to the rest of the industry.
A Quick Ratio of 2.30 indicates that QGEN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.30, QGEN is in line with its industry, outperforming 50.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.18% over the past year.
QGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.92% yearly.
Looking at the last year, QGEN shows a small growth in Revenue. The Revenue has grown by 5.32% in the last year.
Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.32% on average per year.
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.41% yearly.
QGEN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.12% yearly.
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
QGEN is valuated rather expensively with a Price/Earnings ratio of 20.38.
91.23% of the companies in the same industry are more expensive than QGEN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of QGEN to the average of the S&P500 Index (27.19), we can say QGEN is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 18.63, the valuation of QGEN can be described as rather expensive.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaper than 92.98% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.88. QGEN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.38 | ||
| Fwd PE | 18.63 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaper than 91.23% of the companies in the same industry.
QGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. QGEN is cheaper than 87.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.16 | ||
| EV/EBITDA | 14.16 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.62
PEG (5Y)2.57
EPS Next 2Y7.68%
EPS Next 3Y8.33%
5. Dividend
5.1 Amount
QGEN has a yearly dividend return of 0.56%, which is pretty low.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.09. QGEN pays more dividend than 94.74% of the companies in the same industry.
With a Dividend Yield of 0.56, QGEN pays less dividend than the S&P500 average, which is at 1.90.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
5.2 History
QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y7.68%
EPS Next 3Y8.33%
48.29
-0.16 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners85.46%
Inst Owner Change0%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.47B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts74.17
Price Target51.47 (6.59%)
Short Float %3.17%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-0.39%
PT rev (3m)-1.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.96%
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.38 | ||
| Fwd PE | 18.63 | ||
| P/S | 5.06 | ||
| P/FCF | 22.16 | ||
| P/OCF | 15.92 | ||
| P/B | 2.87 | ||
| P/tB | 13.13 | ||
| EV/EBITDA | 14.16 |
EPS(TTM)2.37
EY4.91%
EPS(NY)2.59
Fwd EY5.37%
FCF(TTM)2.18
FCFY4.51%
OCF(TTM)3.03
OCFY6.28%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.62
PEG (5Y)2.57
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.62 |
F-Score8
WACC8.42%
ROIC/WACC0.88
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.16%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
Can you provide the valuation status for QIAGEN N.V.?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What is the earnings growth outlook for QIAGEN N.V.?
The Earnings per Share (EPS) of QIAGEN N.V. (QGEN) is expected to grow by 7.77% in the next year.